InChI=1S/C22H25N3O4S/c1- 2- 29- 22(27) 23- 16- 7- 8- 20- 18(15- 16) 25(17- 5- 3- 4- 6- 19(17) 30- 20) 21(26) 9- 10- 24- 11- 13- 28- 14- 12- 24/h3- 8,15H,2,9- 14H2,1H3,(H,23,27) |
FUBVWMNBEHXPSU-UHFFFAOYSA-N |
CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1 |
|
anti-arrhythmia drug
A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
|
|
View more via ChEBI Ontology
ethyl {10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate
|
moracizina
|
ChemIDplus
|
moracizine
|
KEGG DRUG
|
moracizinum
|
ChemIDplus
|
[10-(3-Morpholin-4-yl-propionyl)-10H-phenothiazin-2-yl]-carbamic acid ethyl ester
|
ChEMBL
|
EN-313
|
ChEMBL
|
ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate
|
ChemIDplus
|
ethyl 10-(β-N-morpholinylpropionyl)phenothiazine-2-carbamate
|
ChEBI
|
Moricizine
|
KEGG COMPOUND
|
1842
|
DrugCentral
|
C07743
|
KEGG COMPOUND
|
D05077
|
KEGG DRUG
|
DB00680
|
DrugBank
|
DE2014201
|
Patent
|
LSM-2476
|
LINCS
|
Moricizine
|
Wikipedia
|
US3740395
|
Patent
|
View more database links |
31883-05-3
|
CAS Registry Number
|
ChemIDplus
|
592021
|
Reaxys Registry Number
|
Reaxys
|
|